Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Apr 11, 2024 04:05 pm ET

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include updates on several ongoing initiatives in the Acute Care f

Mar 28, 2024 04:05 pm ET

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.

Jan 23, 2024 07:00 pm ET

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually –

Jan 07, 2024 04:00 pm ET

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

SAN DIEGO, Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network supporting ZYNRELEF® (bupivacaine and meloxicam) extended-release solution.

Nov 14, 2023 03:05 pm ET

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million and full-year 2024 Net Product Sales to be in the range of $138 million to $158 millionFull-year 2024 EBITDA (excluding stock compensation) expected to be in the range of ($22 million) to $3 millionCost reduction plan implemented decreasing operating expenses (excluding stock compensation and depreciation and am

Nov 07, 2023 03:05 pm ET

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

SAN DIEGO, Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30 p.m. ET to report third quarter 2023 financial results and discuss recent business highlights.

Jul 26, 2023 01:30 pm ET

Northland Capital Markets Institutional Investor Conference

MINNEAPOLIS, MN / ACCESSWIRE / July 26, 2023 / We are pleased to be hosting the Northland Capital Markets Institutional Investor Conference 2023 on Tuesday September 19, 2023, at the Minneapolis Marriott City Center, Downtown Minneapolis. We have over 90 companies to participating. The format will be 10 one-on-one meetings (or small group) scheduled in 35 minute increments.

Jul 24, 2023 09:02 am ET

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

- Expected overall cash savings of $75 million through 2025- New executive management team in place

Jul 24, 2023 09:00 am ET

Heron Therapeutics Announces $30 Million Private Placement Financing

SAN DIEGO, July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purchase agreement to sell in a private placement to institutional investors, led by existing investor Rubric Capital Management LP and including existing and new investors, including Velan Capital, Clearline Capital and Hercules Capital, Inc. (NYSE: HTGC), 20,734,917 shares of its common sto

Jun 23, 2023 04:05 pm ET

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years of experience in a variety of finance and accounting positions, including over a decade in the pharma industry.

Jun 12, 2023 09:00 am ET

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron's Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron's management team and will be responsible for leading clinical and product de

May 11, 2023 04:01 pm ET

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

· Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022

May 04, 2023 04:05 pm ET

Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

SAN DIEGO, May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report first quarter 2023 financial results and discuss recent business highlights.

Apr 20, 2023 09:00 am ET

Heron Therapeutics Announces Commercial Leadership Changes

SAN DIEGO, April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and Marketing, Acute Care, effective April 24, 2023. Mr. Grillot brings more than two decades of hospital experience, most recently serving as a senior sales executive at CHIESI USA.

Apr 17, 2023 04:05 pm ET

Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 17, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Thursday, April 20, 2023, at 11:45 AM ET at the 22nd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 17-20, 2023.

Apr 03, 2023 09:00 am ET

Heron Therapeutics Announces New CEO and Board Chairman

Craig Collard Appointed CEO

Mar 23, 2023 04:05 pm ET

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

- Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 -

Mar 13, 2023 09:00 am ET

Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023

SAN DIEGO, March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration (FDA) for intravenous use in adults for the prevention of postoperat

Feb 27, 2023 03:30 pm ET

Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference

SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat on Tuesday, March 7, 2023 at 2:10 PM ET at the 43rd Annual Cowen Healthcare Conference, being held March 6-8th, 2023 in Boston, MA.

Jan 09, 2023 07:30 am ET

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

- Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 -

Dec 29, 2022 08:00 am ET

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgi

- Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures -

Nov 21, 2022 03:05 pm ET

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat on Thursday, December 1, 2022 at 10:05 AM ET at the Evercore ISI 5th Annual HealthCONX Conference. The conference is being held in a virtual format, November 29-December 1, 2022.

Nov 08, 2022 03:05 pm ET

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

- APONVIE™ approval by FDA, U.S. launch planned for Q1 2023 –

Nov 01, 2022 04:05 pm ET

Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

SAN DIEGO, Nov. 1, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 4:30 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

Sep 16, 2022 02:49 pm ET

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

- APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicatedfor PONV -

Aug 09, 2022 08:01 am ET

Heron Therapeutics Announces $76.5 Million Private Placement Financing

SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purchase agreement to sell in a private placement to a group of new and existing institutional investors, led by Deep Track Capital, LP and including participation from Great Point Partners, Broadfin Holdings, LLC and other leading healthcare investors, 16,129,032 shares of its common stock at

Aug 09, 2022 08:00 am ET

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates

- ZYNRELEF® launch trend continues at a strong pace with sequential quarterly product sales increase of 140% and unit demand increase of 47% -

Aug 02, 2022 04:05 pm ET

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

Jun 30, 2022 08:30 am ET

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend -

Jun 14, 2022 08:30 am ET

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total

SAN DIEGO, June 14, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution as the foundation of a perioperative non-opioid multimodal analgesic (MMA) regimen in patients undergoing total knee arthroplasty (TKA). ZYNRELEF is approved by the U.S. Food and Drug Administ

May 26, 2022 04:05 pm ET

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

SAN DIEGO, May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that company management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 8:30 am ET. The conference is taking place June 8-10th, 2022 in New York, NY.

May 26, 2022 07:30 am ET

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , May 26, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Heron Therapeutics, Inc. (NASDAQ: HRTX).

May 16, 2022 04:05 pm ET

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting

- New interim data from Phase 2 study suggests ZYNRELEF was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections -

May 09, 2022 04:05 pm ET

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter -

May 03, 2022 04:05 pm ET

Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

SAN DIEGO, May 3, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, May 9, 2022 at 4:30 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.

Apr 05, 2022 04:05 pm ET

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

SAN DIEGO, April 5, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on Monday, April 11, 2022 at 8:00 am PT/11:00 am ET.

Mar 25, 2022 08:30 am ET

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care

- ZYNRELEF is the only local anesthetic with separate reimbursement in both the Hospital Outpatient and Ambulatory Surgical Center settings of care -

Mar 17, 2022 08:30 am ET

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

- ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada -

Mar 02, 2022 03:05 pm ET

Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 at 11:10 am PT/2:10 pm ET.

Feb 28, 2022 03:05 pm ET

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted recent corporate updates.

Feb 22, 2022 03:05 pm ET

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Dec 09, 2021 07:00 am ET

Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical

Nov 18, 2021 06:30 am ET

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults. HTX-019 is a proprietary intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) r

Nov 11, 2021 03:05 pm ET

Heron Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Heron management will present and host one-on-one meetings at the following investor conferences.

Nov 03, 2021 04:01 pm ET

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2021 and highlighted recent corporate updates.

Oct 28, 2021 08:30 am ET

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Wednesday, November 3, 2021 at 4:15 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

Oct 04, 2021 08:30 am ET

Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting

SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced submission of a supplemental New Drug Application (NDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution for an expanded indication. ZYNRELEF is currently indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open i

Sep 21, 2021 04:05 pm ET

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer, and John Poyhonen, President and Chief Commercial Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 1:20 pm ET.

Aug 09, 2021 08:00 am ET

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and six months ended June 30, 2021 and highlighted recent corporate updates.

Jul 28, 2021 04:05 pm ET

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled, "Opioid-Free Recovery After Hernia Repair With HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Settin

Jul 21, 2021 04:05 pm ET

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the online publication of new analysis evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies. The analysis, published in the peer-reviewed journal Pai

Jul 06, 2021 08:30 am ET

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has executed a contract for ZYNRELEF with Apexus, LLC (Apexus). Apexus is the designated Prime Vendor for the 340B Drug Pricing Program. ZYNRELEF was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical a

Jul 01, 2021 08:30 am ET

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced ZYNRELEF (bupivacaine and meloxicam) extended-release solution, is now commercially available at all national wholesalers and the largest specialty distributors in the United States. ZYNRELEF was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2021, for use in adults for soft tissue or periarticular

Feb 24, 2021 07:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.

Feb 17, 2021 03:05 pm ET

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences

SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron Therapeutics, will present at the following virtual investor conferences:

Jan 21, 2021 07:30 am ET

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from an EPOCH 1 follow-on study (NCT03718039) of the investigational agent HTX-011 in bunionectomy, have been published online, by the Journal of the American Podiatric Medical Association in an article entitled "Opioid-Free Recovery from Bunionectomy with HTX-011, a Dual-Acting Local Anesthetic Comb

Jan 11, 2021 07:30 am ET

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlights progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises and announces a new development program for postoperative nausea and vomiting (PONV).

Nov 13, 2020 07:30 am ET

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for HTX-011, an investigational agent for the management of postoperative pain.

Nov 11, 2020 03:05 pm ET

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron Therapeutics, will present at the following virtual investor conferences:

Nov 05, 2020 07:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2020 and highlighted recent corporate updates.

Aug 05, 2020 04:05 pm ET

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and six months ended June 30, 2020 and highlighted recent corporate updates.

Jul 24, 2020 08:30 am ET

Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain

SAN DIEGO, July 24, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for ZYNRELEF (formerly known as HTX-011), intended for the treatment of postoperative pain.

Jul 16, 2020 08:30 am ET

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

SAN DIEGO, July 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Administration (FDA) of Heron's Investigational New Drug appli

Jun 29, 2020 08:45 am ET

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on June 26, 2020 regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

Jun 04, 2020 09:00 am ET

Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

SAN DIEGO, June 4, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from Study 209, a Phase 2b study of the investigational agent HTX-011 in primary unilateral total knee arthroplasty (TKA), have been published online by The Journal of Arthroplasty in an article entitled "HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomize

May 18, 2020 09:00 am ET

Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain

SAN DIEGO, May 18, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has initiated a Phase 1b/2 clinical study in patients undergoing bunionectomy of HTX-034, Heron's next-generation product for the treatment of postoperative pain. The study initiation follows clearance from the U.S. Food and Drug Administration (FDA) of Heron's Investigational New Drug application for HTX-034

May 06, 2020 09:00 am ET

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, May 6, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2020 and highlighted recent corporate updates.

Apr 09, 2020 04:05 pm ET

Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 9, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th, 2020 at 2:50 p.m. ET. The conference is being held in a virtual format.

Nov 14, 2019 03:05 pm ET

Heron Therapeutics to Present at the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 5:20 p.m. GMT (12:20 p.m. EST) at the Waldorf Hilton London hotel.

Nov 13, 2019 03:05 pm ET

Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 8:35 a.m. EST at the Lotte New York Palace hotel.

Nov 12, 2019 07:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2019 and highlighted recent corporate updates.

Oct 28, 2019 08:30 am ET

Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain. The FDA set a PDUFA goal date of March 26, 2020.

Oct 22, 2019 08:30 am ET

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion for intravenous (IV) use. The sNDA requested FDA approval to expand the recommended dosage to include the 130 mg single-dose regimen for patients receiving MEC.

Oct 04, 2019 10:00 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc. (NASDAQ: HRTX), Immunomedics, Inc. (NASDAQ: IMMU), and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) on...

Oct 03, 2019 10:37 pm ET

Heron Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price of $17.50 per share. In addition, Heron has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of its common stock on the same terms and conditions. The of

Oct 03, 2019 04:01 pm ET

Heron Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. Heron intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares sold in the public offering. All of the shares of common stock in the offering

Oct 02, 2019 07:45 am ET

Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty

SAN DIEGO, Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results of a multi-center postoperative pain management study in which 51 patients undergoing total knee arthroplasty (TKA) surgery received the investigational agent, HTX-011, together with a scheduled postoperative regimen of generic, oral analgesics (acetaminophen and celecoxib). A follow-on study

Oct 01, 2019 04:10 pm ET

Heron Therapeutics Appoints Kimberly Manhard to Board of Directors

Oct 01, 2019 04:05 pm ET

Heron Therapeutics Appoints Stephen Davis to Board of Directors

Oct 01, 2019 08:30 am ET

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011, an investigational agent for the management of postoperative pain. The Company anticipates a 6-month review by the FDA.

Sep 25, 2019 04:05 pm ET

Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 2:25 p.m. EDT at the InterContinental New York Barclay hotel.

Aug 20, 2019 08:30 am ET

Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

SAN DIEGO, Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from EPOCH 2, a Phase 3 study of the investigational agent HTX-011 in open inguinal hernia repair surgery with mesh, have been published in the journal, Hernia, in an article entitled "HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phas

Aug 05, 2019 03:00 pm ET

Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Heron securities between October 31, 2018 and April 30, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/hrtx.

Aug 05, 2019 08:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and six months ended June 30, 2019 and highlighted recent corporate updates.

Aug 05, 2019 08:15 am ET

MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ: HRTX) for violations of §§10(b) and 20(a) of the Securities...

Aug 02, 2019 03:00 pm ET

Final Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX) and certain of its officers, on behalf of...

Aug 02, 2019 09:43 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, STG, PVTL and GTT

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Aug 02, 2019 07:10 am ET

Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...

Aug 01, 2019 02:46 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. (“Heron”) or the (“Company”) (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class...

Jul 31, 2019 12:53 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX) and certain of its officers. The class action, filed in United States District Court, for the Southern...

Jul 30, 2019 06:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Beazer Homes, and Cloudera and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Heron Therapeutics, Inc., Box, Inc., Beazer Homes USA, Inc., and Cloudera, Inc. Stockholders have until the deadlines below to...

Jul 30, 2019 11:20 am ET

CLASS ACTION UPDATE for MMM, HRTX, CTST and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Jul 30, 2019 10:47 am ET

HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 6 Days Remain To Make A Motion For Lead Plaintiff In A Securities Class Action Lawsuit Against Heron Therapeutic

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately six days remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jul 29, 2019 01:32 pm ET

ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important August 5th Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact

Jul 29, 2019 09:10 am ET

7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jul 26, 2019 03:00 pm ET

Heron Therapeutics, Inc. (HRTX), Beazer Homes USA, Inc. (BZH) & Ascena Retail Group, Inc. (ASNA) - Bronstein, Gewirtz & Grossman, LLC Class Action Update

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Jul 26, 2019 09:21 am ET

Zhang Investor Law Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks...

Jul 25, 2019 10:21 am ET

HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 11 Days Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately eleven days remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jul 23, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against A.O. Smith Corporation, Community Health Systems, Metro Bank, and Heron Therapeutics and Encourages Inv

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of A.O. Smith Corporation, Community Health Systems, Inc., Metro Bank PLC, and Heron Therapeutics, Inc. Stockholders have until...

Jul 23, 2019 06:21 pm ET

Federman & Sherwood Reminds Investors of Imminent Lead Plaintiff Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

On June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc. (NASDAQ: HRTX). Federman & Sherwood reminds current and former shareholders of Heron Therapeutics, Inc. that they only have until Monday, August 5, 2019 to move the court for appointment as a lead plaintiff in this case. The Complaint alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act, and Rule 10b-5 promulgated thereunder.

Jul 23, 2019 05:00 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Jul 22, 2019 05:16 pm ET

Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jul 22, 2019 10:10 am ET

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the F

Jul 20, 2019 12:00 pm ET

ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important August 5th Deadline in the Securities Class Action – HRTX

Jul 19, 2019 03:00 pm ET

Metro Bank PLC (MBNKF), Heron Therapeutics, Inc. (HRTX) & Beazer Homes USA, Inc. (BZH) - Bronstein, Gewirtz & Grossman, LLC Class Action Update

Jul 17, 2019 09:14 am ET

CLASS ACTION UPDATE for HRTX, PVTL, RMED and ZUO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 16, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Cloudera, and Mammoth Energy and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Heron Therapeutics, Inc., Box, Inc, Cloudera, Inc., and Mammoth Energy Services, Inc. Stockholders have until the deadlines...

Jul 16, 2019 08:01 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Jul 16, 2019 01:38 pm ET

HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 2 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately two weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jul 15, 2019 11:30 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir

Jul 12, 2019 04:16 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

NEW YORK, July 12, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. ("Heron") or the ("Company") (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 12, 2019 03:00 pm ET

Hecla Mining Company (HL), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Update

Jul 12, 2019 11:58 am ET

Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jul 11, 2019 09:29 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, EQT, DBD and INS

Jul 10, 2019 04:53 pm ET

Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jul 10, 2019 01:45 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Jul 09, 2019 11:36 am ET

HRTX Class Action Deadline: Bernstein Liebhard LLP Reminds Investors That Approximately 3 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately 3 weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jul 08, 2019 06:25 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Jul 08, 2019 11:25 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi

Jul 08, 2019 09:36 am ET

CLASS ACTION UPDATE for HRTX, STG, PYX and ZUO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 05, 2019 03:00 pm ET

Intersect ENT, Inc. (XENT), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

Jul 02, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Cloudera, and Mammoth Energy and Encourages Investors to Contact the Firm

Jul 02, 2019 11:19 am ET

Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jul 01, 2019 03:58 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Jul 01, 2019 02:20 pm ET

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Jun 28, 2019 04:40 pm ET

HRTX Class Action Deadline: Bernstein Liebhard LLP Reminds Investors That Approximately 5 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately five weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jun 28, 2019 03:00 pm ET

Intersect ENT, Inc. (XENT), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

Jun 27, 2019 04:05 pm ET

CLASS ACTION UPDATE for AOS, HRTX, BOX and FDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jun 27, 2019 02:28 pm ET

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ:

Jun 26, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Cloudera, and Mammoth Energy and Encourages Investors to Contact the Firm

Jun 26, 2019 04:33 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Jun 26, 2019 04:01 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Jun 25, 2019 11:20 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir

Jun 22, 2019 10:15 am ET

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM: Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jun 21, 2019 04:11 pm ET

Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jun 21, 2019 03:00 pm ET

Intersect ENT, Inc. (XENT), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

Jun 19, 2019 09:37 am ET

SHAREHOLDER ALERT: PSMT INVVY MOMO HRTX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Jun 18, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache and Encourages Investors to Contact the Fi

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache. Stockholders have until the deadlines listed below to petition...

Jun 18, 2019 08:00 pm ET

TOP RANKED ROSEN LAW FIRM: Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – HRTX

Jun 18, 2019 04:48 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX

Jun 18, 2019 02:47 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Jun 18, 2019 12:59 pm ET

HRTX Class Action Deadline: Bernstein Liebhard LLP Reminds Investors That Approximately 7 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately seven weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...

Jun 18, 2019 11:00 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi

Jun 17, 2019 08:39 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - HRTX

NEW YORK, June 17, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX) and certain of its officers. The class action, filed in United States District Court, for the Southern District of California, and indexed under 19-cv-01038, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Heron securities between October 31, 2018 and April 30, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations

Jun 17, 2019 09:10 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APYX, NOK, HRTX and TUSK

Jun 14, 2019 04:36 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Heron Therapeutics, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ:

Jun 14, 2019 03:44 pm ET

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Jun 14, 2019 03:00 pm ET

Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Update

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Jun 13, 2019 06:18 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Heron Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) securities between October 31, 2018 and Apr

Jun 12, 2019 04:29 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Jun 12, 2019 12:46 pm ET

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Jun 10, 2019 04:12 pm ET

HERON THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for Southern Dist

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that acquired Heron Therapeutics,...

Jun 07, 2019 05:27 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Heron Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ:

Jun 07, 2019 12:12 pm ET

Robbins Arroyo LLP: Heron Therapeutics, Inc. (HRTX) Misled Shareholders According to a Recently Filed Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Heron Therapeutics, Inc. (NASDAQ: HRTX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 31, 2018 and April 30, 2019. Heron Therapeutics is a biotechnology company tha

Jun 06, 2019 06:23 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Heron Therapeutics, Inc. Investors (HRTX)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) securities between October 31, 2018 and April 30, 2019, inclusive (the “Class Period”). Heron Therapeutics investors

Jun 06, 2019 01:33 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir

Jun 05, 2019 09:00 pm ET

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Heron Therapeutics, Inc. Investors (HRTX)

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) investors concerning the Company and its officers’ possible violations of federal securities laws.

Jun 05, 2019 07:55 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Heron Therapeutics, Inc. Investors (HRTX)

Law Offices of Howard G. Smith announces an investigation on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) investors concerning the Company and its officers’ possible violations of federal securities laws.

Jun 05, 2019 06:55 pm ET

HRTX REMINDER: ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Con

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”) of the important August 5, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Heron investors under the federal securities laws.

Jun 05, 2019 03:00 pm ET

Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: August 5, 2019

Jun 05, 2019 12:00 pm ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ:

Jun 05, 2019 10:11 am ET

CLASS ACTION UPDATE for PSMT and HRTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jun 04, 2019 09:00 pm ET

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. (NASDAQ: HRTX) and Encourages Heron Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Heron Therapeutics, Inc....

Jun 04, 2019 04:25 pm ET

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood announces that on June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc. (NASDAQ: HRTX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is Octobe

Jun 04, 2019 01:46 pm ET

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ:

Jun 04, 2019 11:16 am ET

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Heron investors under the federal securities laws.

Jun 04, 2019 09:53 am ET

Pomerantz Law Firm Announces the Filing of a Class Action against Heron Therapeutics, Inc. and Certain Officers – HRTX

May 21, 2019 09:13 am ET

Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy

SAN DIEGO, May 21, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from the pivotal Phase 3 EPOCH 1 bunionectomy study of the investigational agent HTX-011 have been published online by the Regional Anesthesia & Pain Medicine (RAPM) journal. The article, entitled "HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase

May 14, 2019 03:36 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX

Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....

May 14, 2019 08:30 am ET

Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen

SAN DIEGO, May 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in 93 patients that provides real-world evidence of opioid-free recovery in patients undergoing outpatient inguinal hernia repair surgery who received the investigational agent, HTX-011, together with a scheduled background regimen of generic over-the-count

May 13, 2019 05:23 pm ET

Lifshitz & Miller LLP Announces Investigation of 3M Company, Aquantia Corporation, Chesapeake Lodging Trust, Fluor Corporation, Gardner Denver Holdings, Inc., Heron Therapeutics, Inc., Intermolecular,

NEW YORK, May 13, 2019 /PRNewswire/ --

May 09, 2019 08:30 am ET

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress

SAN DIEGO, May 9, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress.

May 08, 2019 04:05 pm ET

Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, at 11:35 a.m. PDT at the Encore Hotel in Las Vegas, NV.

May 07, 2019 04:05 pm ET

Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States

SAN DIEGO, May 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced they joined the National Academy of Medicine's (NAM) Action Collaborative on Countering the U.S. Opioid Epidemic (Action Collaborative).

May 02, 2019 03:00 pm ET

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Heron Therapeutics, Inc. (HRTX)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX). Such investors are encouraged to obtain additional...

May 01, 2019 09:15 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX

NEW YORK, May 1, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

May 01, 2019 09:15 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX

NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

May 01, 2019 08:00 am ET

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

SAN DIEGO, May 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 30, 2019 regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

Apr 01, 2019 08:30 am ET

Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management

SAN DIEGO, April 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the Marketing Authorisation Application (MAA) for its investigational agent, HTX-011, for postoperative pain, was validated by the European Medicines Agency (EMA). Validation of the MAA confirms that the submission is complete and starts the EMA's Centralised Procedure. The EMA granted eligibility to the Central

Mar 11, 2019 08:30 am ET

77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy

SAN DIEGO, March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 31 patients undergoing bunionectomy surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in buni

Mar 05, 2019 07:25 am ET

Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Devel

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation (NASDAQ:CZR), Party City Holdco Inc....

Mar 04, 2019 03:05 pm ET

Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

SAN DIEGO, March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place.

Feb 26, 2019 03:05 pm ET

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion, for intravenous (IV) use. The sNDA requested FDA approval to expand the administration of CINVANTI beyond the already approved administration method (a 30-minut

Feb 22, 2019 07:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress

SAN DIEGO, Feb. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2018 and highlighted recent corporate progress.

Feb 20, 2019 03:05 pm ET

Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel.

Feb 05, 2019 03:30 pm ET

Heron Therapeutics Announces Retirement of Robert Rosen as President

SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Robert Rosen, President, will be retiring. Mr. Rosen's responsibilities will be transitioned to Barry Quart, Pharm.D., Chief Executive Officer of Heron, who will take on the additional role of President.

Jan 30, 2019 07:35 am ET

New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star...

Jan 07, 2019 07:30 am ET

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises.

Jan 03, 2019 07:30 am ET

90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study

SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 63 patients undergoing hernia repair surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in herni

Dec 31, 2018 03:05 pm ET

Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA.

Dec 31, 2018 07:30 am ET

FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. HTX-011 is a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the ant

Nov 27, 2018 07:50 am ET

Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), Extreme Networks, Inc....

Nov 20, 2018 03:05 pm ET

Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 20, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, at 10:15 a.m. EST at the Boston Harbor Hotel.

Nov 12, 2018 03:01 pm ET

U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics

SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside chat with the U.S. Surgeon General, Vice Admiral Jerome M. Adams, M.D., M.P.H. It was a familiar venue for Dr. Adams, as he continues to visit communities across the country and advocate for forming non-traditional partnerships with businesses, faith-based communities and law enforcement agencies to tackle th

Nov 07, 2018 03:05 pm ET

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2018 and highlighted recent corporate progress.

Oct 31, 2018 04:01 pm ET

Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management

SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative

Oct 12, 2018 07:40 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Ec

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloud Peak Energy Inc (NYSE:CLD), Ralph Lauren Corporation (NYSE:RL),...

Sep 24, 2018 04:05 pm ET

Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 2:20 p.m. EDT at the Intercontinental New York Barclay Hotel.

Aug 13, 2018 08:00 am ET

New Research Coverage Highlights East West, Heron Therapeutics, Invacare, CNO Financial Group, Fortinet, and Realogy — Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of East West Bancorp, Inc. (NASDAQ:EWBC), Heron Therapeutics, Inc....

Aug 08, 2018 08:30 am ET

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

SAN DIEGO, Aug. 8, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and six months ended June 30, 2018 and highlighted recent corporate progress.

You are here

Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research